New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Bazargan
Ali
A
St Vincent's Hospital, Melbourne, Australia.
Tam
Constantine S
CS
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002872:Chromosome Deletion; D003520:Cyclophosphamide / Q000008:administration & dosage; D004358:Drug Therapy / Q000379:methods; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008495:Medical Oncology / Q000379:methods; D012306:Risk; D000069283:Rituximab; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D013792:Thalidomide; D003520:Cyclophosphamide; D000077269:Lenalidomide; D014740:Vidarabine; C024352:fludarabine